Breast cancer patients over the age of 60 with early-stage, hormone-responsive small tumors who forego adjuvant endocrine, also called hormonal therapy, are not at an increased risk of mortality compared to women of the same age without breast cancer, according to a study published Aug. 31 in the Journal of the National Cancer Institute. The use of hormonal therapy has increased in breast cancer patients overall, and the 2009 St. Gallen International Breast Cancer Conference recommended hormonal therapy for almost all patients with hormone-responsive disease...
More...
More...